以多西他賽為基礎的三藥對比兩藥輔助化學療法對胃癌根治術后臨床療效分析_《華西醫學》

作者：

毛志遠 , 郭曉川 , 蘇丹 , 張婷婷 ,  白莉

解放軍總醫院腫瘤內科（北京，100853）;

關鍵詞：

胃癌多西他賽輔助化學療法療效分析

DOI：

10.7507/1002-0179.20130492

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　觀察多西他賽三藥及兩藥聯合對胃癌根治術后輔助化學療法（化療）的療效比較及不良反應。方法　回顧性分析解放軍總醫院2006年1月－2011年12月42 例胃癌根治術后患者的臨床資料，其中有22例、20例患者分別接受以多西他賽為基礎的三藥、兩藥聯合輔助化療。三藥聯合：多西他賽注射液+鉑類+氟尿嘧啶/卡培他濱片/替吉奧；兩藥聯合：多西他賽注射液+氟尿嘧啶/卡培他濱片/替加氟或多西他賽注射液+鉑類；主要觀察終點：無疾病生存期（DFS），次要觀察終點：預后因素分析、復發轉移情況、不良反應及亞組分析。結果　兩組中位DFS分別為9.530、7.170個月（P=0.646）；性別、年齡、腫瘤浸潤深度、脈管癌栓、淋巴結清掃范圍是患者早期復發轉移的不良預后因素，三藥聯合組肝轉移率高于兩藥聯合組（P=0.008）；主要不良反應為惡心、嘔吐、白細胞減少、腹瀉、脫發、血小板減少等，多為1～2級，可耐受，三藥聯合組較兩藥聯合組易出現不良反應（P=0.011），以惡心、嘔吐為主。結論　胃癌根治術后以多西他賽為基礎的輔助化療三藥、兩藥聯合對患者療效及預后無明顯差異，且兩種輔助療法不良反應基本可耐受。

引用本文： 毛志遠,郭曉川,蘇丹,張婷婷,白莉. 以多西他賽為基礎的三藥對比兩藥輔助化學療法對胃癌根治術后臨床療效分析. 華西醫學, 2013, 28(10): 1559-1563. doi: 10.7507/1002-0179.20130492 復制

1.	Catalano V, Labianca R, Beretta GD, et al. Gastric cancer[J]. Crit Rev Oncol Hematol, 2009, 71(2): 127-164.
2.	Crew KD, Neugut A. Epidemiology of gastric cancer[J]. World J Gastroenterol, 2006, 12(3): 354-362.
3.	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
4.	Deng J, Liang H, Wang D, et al. Investigation of the recurrence patterns of gastric cancer following a curative resection[J]. Surg Today, 2011, 41(2): 210-215.
5.	La Torre M, Rossi Del Monte S, Ferri M, et al. Peritoneal washing cytology in gastric cancer. How, When and who will get a benifit. A review[J]. Minerva Gastroenterol Dietol, 2011, 57(1): 43-51.
6.	Kim JH, Park SS, Park SH, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer[J]. J Surg Res, 2010, 162(2): 177-183.
7.	吳亮亮, 梁寒, 王曉娜, 等. 胃癌根治術后早期復發轉移的相關因素分析[J]. 中華外科雜志, 2010, 48(20): 1542-1545.
8.	Japanese Gatric Cancer Association. Japanese classification of gastric carcinoma. 2nd English Edition[J]. Gastric Cancer, 1998, 1(1): 10-24.
9.	Ito S, Nakanishi H, Kodera Y, et al. Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients[J]. Br J Cancer, 2005, 93(9): 986-992.
10.	Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer[J]. Am J Surg, 2006, 192(3): 296-300.
11.	Huang KH, Chen JH, Wu CW, et al. Factors affecting recurrence in node-negative advanced gastric cancer[J]. J Gastroenterol Hepatol, 2009, 24(9): 1522-1526.
12.	Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses[J]. Tumori, 2002, 88(1): 21-27.
13.	Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
14.	Mezhir JJ, Pillarisetty VG, Shah MA, et al. Randomized clinical trials in gastric cancer[J]. Surg Oncol Clin N Am, 2010, 19(1): 81-100.
15.	Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric Cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18): 1810-1820.
16.	Nakata B, Tsuji A, Mitachi Y, et al. PhaseⅡ trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2)[J]. Oncology, 2010, 79(5-6): 337-342.
17.	Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321.
18.	Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phaseⅡ trial[J]. Am J Clin Oncol, 2000, 23(4): 341-344.
19.	Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/m2 is active and well tolerated in patients with metaststic or recurrent gastic cancer: a phase Ⅱ trial[J]. Jpn J Clin Oncol, 2002, 32(7): 248-254.
20.	Moehler MH, Thuss-Patience P, Arndd D, et al. Docetaxel, oxaliplatin, and Capecitabine(TEX regimen)for patients with meta static gastric cancer:interim results from a phaseⅡ trial by the German AIO Group[J]. J Clin Oncol (Meeting Abstracts), 2009, 27(1): 45-54.
21.	Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ)adenocarcinomas: preliminary results of a phaseⅡ study[J]. Gastrointestinal Cancers Synposium, 2009, 23(1): 47.

1. 　Catalano V, Labianca R, Beretta GD, et al. Gastric cancer[J]. Crit Rev Oncol Hematol, 2009, 71(2): 127-164.
2. 　Crew KD, Neugut A. Epidemiology of gastric cancer[J]. World J Gastroenterol, 2006, 12(3): 354-362.
3. 　Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
4. 　Deng J, Liang H, Wang D, et al. Investigation of the recurrence patterns of gastric cancer following a curative resection[J]. Surg Today, 2011, 41(2): 210-215.
5. 　La Torre M, Rossi Del Monte S, Ferri M, et al. Peritoneal washing cytology in gastric cancer. How, When and who will get a benifit. A review[J]. Minerva Gastroenterol Dietol, 2011, 57(1): 43-51.
6. 　Kim JH, Park SS, Park SH, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer[J]. J Surg Res, 2010, 162(2): 177-183.
7. 　吳亮亮, 梁寒, 王曉娜, 等. 胃癌根治術后早期復發轉移的相關因素分析[J]. 中華外科雜志, 2010, 48(20): 1542-1545.
8. 　Japanese Gatric Cancer Association. Japanese classification of gastric carcinoma. 2nd English Edition[J]. Gastric Cancer, 1998, 1(1): 10-24.
9. 　Ito S, Nakanishi H, Kodera Y, et al. Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients[J]. Br J Cancer, 2005, 93(9): 986-992.
10. 　Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer[J]. Am J Surg, 2006, 192(3): 296-300.
11. 　Huang KH, Chen JH, Wu CW, et al. Factors affecting recurrence in node-negative advanced gastric cancer[J]. J Gastroenterol Hepatol, 2009, 24(9): 1522-1526.
12. 　Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses[J]. Tumori, 2002, 88(1): 21-27.
13. 　Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
14. 　Mezhir JJ, Pillarisetty VG, Shah MA, et al. Randomized clinical trials in gastric cancer[J]. Surg Oncol Clin N Am, 2010, 19(1): 81-100.
15. 　Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric Cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18): 1810-1820.
16. 　Nakata B, Tsuji A, Mitachi Y, et al. PhaseⅡ trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2)[J]. Oncology, 2010, 79(5-6): 337-342.
17. 　Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321.
18. 　Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phaseⅡ trial[J]. Am J Clin Oncol, 2000, 23(4): 341-344.
19. 　Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/m2 is active and well tolerated in patients with metaststic or recurrent gastic cancer: a phase Ⅱ trial[J]. Jpn J Clin Oncol, 2002, 32(7): 248-254.
20. 　Moehler MH, Thuss-Patience P, Arndd D, et al. Docetaxel, oxaliplatin, and Capecitabine(TEX regimen)for patients with meta static gastric cancer:interim results from a phaseⅡ trial by the German AIO Group[J]. J Clin Oncol (Meeting Abstracts), 2009, 27(1): 45-54.
21. 　Shankaran V, Mulcahy MF, Hochster HS, et al. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ)adenocarcinomas: preliminary results of a phaseⅡ study[J]. Gastrointestinal Cancers Synposium, 2009, 23(1): 47.

《華西醫學》

以多西他賽為基礎的三藥對比兩藥輔助化學療法對胃癌根治術后臨床療效分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

以多西他賽為基礎的三藥對比兩藥輔助化學療法對胃癌根治術后臨床療效分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料